| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
Seralutinib (PK-10571; GB-002) is a novel and potent PDGFRα/β inhibitor used as an inhaled formulation for the treatment of PAH (pulmonary arterial hypertension). In a Su5416 Hypoxia Rat Model with PAH, seralutinib shows excellent in vivo efficacy.
| Targets |
CSF1R (IC50 = 8 nM); c-KIT (IC50 = 14 nM); PDGFRβ; PDGFRα
|
|---|---|
| ln Vivo |
Seralutinib (GB002) (treated respiratory, inhaled) significantly lowered right ventricular systolic pressure and mean pulmonary artery pressure. In Seralutinib (GB002)-treated mice, hemodynamic alterations were accompanied by reduced muscularization of pulmonary arterioles and lobar Seralutinib (GB002) was well tolerated [1]. GB002-mediated suppression of lung PDGFRα/β phosphorylation after adsorption to healthy Sprague Dawley [2]. Seralutinib is dose- and time-regulated. Induces lung BMPR2 protein expression [2].
|
| References |
|
| Molecular Formula |
C27H27N5O3
|
|---|---|
| Molecular Weight |
469.545
|
| Exact Mass |
469.211
|
| Elemental Analysis |
C, 69.07; H, 5.80; N, 14.92; O, 10.22
|
| CAS # |
1619931-27-9
|
| Related CAS # |
1619931-27-9
|
| PubChem CID |
91663352
|
| Appearance |
White to light yellow solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
601.4±55.0 °C at 760 mmHg
|
| Flash Point |
317.5±31.5 °C
|
| Vapour Pressure |
0.0±1.7 mmHg at 25°C
|
| Index of Refraction |
1.649
|
| LogP |
3.01
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
35
|
| Complexity |
667
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
O(C)C1=C(C=CC(=C1)C1=CN=CC(=N1)N[C@@H](C)C1C=CC=C(C=1)NC(C1C=NC=C(C)C=1)=O)OC
|
| InChi Key |
JHJNPOSPVGRIAN-SFHVURJKSA-N
|
| InChi Code |
InChI=1S/C27H27N5O3/c1-17-10-21(14-28-13-17)27(33)31-22-7-5-6-19(11-22)18(2)30-26-16-29-15-23(32-26)20-8-9-24(34-3)25(12-20)35-4/h5-16,18H,1-4H3,(H,30,32)(H,31,33)/t18-/m0/s1
|
| Chemical Name |
N-[3-[(1S)-1-[[6-(3,4-dimethoxyphenyl)pyrazin-2-yl]amino]ethyl]phenyl]-5-methylpyridine-3-carboxamide
|
| Synonyms |
Seralutinib; PK-10571; GB002; PK10571; GB-002; PK 10571; GB 002
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 94~200 mg/mL (200.2~425.96 mM)
Ethanol: ~94 mg/mL (~200.2 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 5.75 mg/mL (12.25 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 57.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.32 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.32 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1297 mL | 10.6485 mL | 21.2970 mL | |
| 5 mM | 0.4259 mL | 2.1297 mL | 4.2594 mL | |
| 10 mM | 0.2130 mL | 1.0648 mL | 2.1297 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT05934526 | Recruiting | Drug: Placebo Drug: Seralutinib |
Pulmonary Arterial Hypertension | GB002, Inc. | September 30, 2023 | Phase 3 |
| NCT04816604 | Recruiting | Drug: GB002 (seralutinib) Device: Generic Dry Powder Inhaler |
Pulmonary Arterial Hypertension | GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. |
April 5, 2021 | Phase 2 |
| NCT04456998 | Completed | Drug: GB002 (seralutinib) Drug: Placebo |
Pulmonary Artery Hypertension | GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. |
November 12, 2020 | Phase 2 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
